Abstract 13P
Background
The limit of detection (LoD) represents the minimum number of reads to detect a variant in a given depth, especially in multigene panel testing (MGPT). The reliability of MGPT depends on LoD in detecting somatic variants with precision. Comparison based LoD calculations require multiple inputs like population and non-tumorous data, which needs a high computational power. The standard MGPTs calculate in-run LoD rather than allele specific. Here, we aim to introduce a single-data-driven parallelized algorithm that overcomes these limitations.
Methods
The algorithm utilizes VCF and BAM files and derives the log-odds score from the binomial probabilities of true positive and false positive along with the variant allele fraction. Subsequently, the algorithm determines the minimum VAF threshold, indicating that the variant is confidently detectable above the specified error rate (default: 0.0001). A total of 652 liquid biopsy samples reported by a MGPT (20 genes), were used for benchmarking. We performed Fisher's exact test (p<0.05) both at the variant and gene-based level to analyze the association between true and false positive predictions.
Results
In our study, we optimized the algorithm's execution time by implementing it in a parallel processing framework. We were able to calculate LoDs in 44.32 kb/min speed within the configuration of 64 cores and 256 GB of memory. Based on reported detectable variants, the algorithm significantly demonstrated 89.92% positive predictive value (p=0.0001). When we assessed the algorithm at the gene-based level, all of 20 cancer-related genes were found statistically significant (p<0.003), which proves our testing accuracy.
Conclusions
The algorithm achieved highly significant associations by overcoming the limitations of comparison-based LoD calculations, both at the variant- and gene-based levels. These findings highlight the potential of our tool to aid precision oncogenomics from liquid biopsy samples. Overall, the study presents a novel LoD tool for all NGS applications, particularly in the scope of MGPT for somatic variants. The tool holds promise in advancing precision oncogenomics and may serve as a valuable asset in all personalized treatment strategies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Acibadem Mehmet Ali Aydinlar University, Institute of Health Sciences, Department of Genome Studies.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract